Corcept Therapeutics - Corcept is a pharmaceutical company engaged in the discovery, development, and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym® is the company’s first FDA-approved medication. Korlym inhibits the effects of excess cortisol in patients with hypercortisolism by modulating activity at the glucocorticoid receptor, one of the two receptors to which cortisol binds. Stop by our booth #1037 to learn more about the deleterious effects of Hypercortisolism, if left untreated.
Brands: Korlym (mifepristone) 300 mg Tablets